RBOT:NYE-Vicarious Surgical Inc. (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 5.57

Change

-0.45 (-7.48)%

Market Cap

USD 0.05B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-04 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

N/A

USD 237.84B
MDT Medtronic PLC

N/A

USD 121.20B
ZBH Zimmer Biomet Holdings Inc

N/A

USD 22.25B
STE STERIS plc

N/A

USD 22.15B
SNN Smith & Nephew SNATS Inc

N/A

USD 13.02B
PEN Penumbra Inc

N/A

USD 10.50B
GMED Globus Medical

N/A

USD 9.77B
BIO Bio-Rad Laboratories Inc

N/A

USD 7.36B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 7.34B
GKOS Glaukos Corp

N/A

USD 5.78B

ETFs Containing RBOT

XBM:CA iShares S&P/TSX Global Ba.. 10.88 % 0.62 %

N/A

CAD 0.23B
SLX VanEck Steel ETF 10.82 % 0.56 %

N/A

N/A
HAP VanEck Natural Resources .. 2.05 % 0.50 %

N/A

USD 0.15B
FLLV 1.74 % 0.50 %

N/A

N/A
SCID 0.51 % 0.39 %

N/A

N/A
JPEU 0.46 % 0.40 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -57.67% 9% A- 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.67% 9% A- 1% F
Trailing 12 Months  
Capital Gain -32.24% 27% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.24% 27% F 12% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 14.41% 67% D+ 76% C+
Dividend Return 14.41% 67% D+ 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 313.35% 6% D- 3% F
Risk Adjusted Return 4.60% 52% F 25% F
Market Capitalization 0.05B 10% F 20% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector